The city of Ocala, Florida, currently has 7 active clinical trials seeking participants for Breast Cancer research studies.
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT05654623
Recruiting
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Florida Cancer Specialists, Ocala, Florida
Conditions: Advanced Breast Cancer
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Florida Cancer Specialists - North Region Research Office,4945 SW 49th Place, Ocala, Florida
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Ocala Oncology, Ocala, Florida
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT05963984
Recruiting
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: SCRI - Florida Cancer Specialists - North Region R,4945 SW 49th Place, Ocala, Florida
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526
Recruiting
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Ocala Oncology Florida Cancer Affiliates, Ocala, Florida
Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Register for Updates
Breast Cancer Liquid Biopsy Trial
NCT04962529
Recruiting
The purpose of this study is to continue to develop a liquid biopsy (minimally invasive blood test) that can be used to confirm if breast cancer has spread throughout the body and if this liquid biopsy test can provide comparable information to a highly invasive tissue biopsy. The knowledge gained in this study could be used in future studies to confirm cancer recurrence using a safe and minimally invasive procedure. The research will consist of looking for tumor cell(s) circulating in the blood... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/08/2022
Locations: Ocala Oncology, Ocala, Florida
Conditions: Breast Cancer, Cancer
Register for Updates